.jpg?format=webp&width=780)
The study evaluated SIM0417 (with ritonavir) as a significant reduction in viral load compared to the placebo on Day 4. Both active groups had fewer positive SARS-CoV-2 cases. The median time for symptom alleviation was shorter in the high-dose group (2.0 days) compared to the placebo group (6.0 days). SIM0417 plus ritonavir were well-tolerated with only mild adverse events. The study recommended 750 mg SIM0417 plus 100 mg ritonavir as the preferred clinical dose.
Like
Save
Share